| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2466382 | Veterinary Microbiology | 2016 | 7 Pages |
•Recombinant endolysin Trx-SA1 derived from Staphylococcus aureus bacteriophage IME-SA1 was successfully obtained.•Trx-SA1 could effectively treat dairy cow mastitis caused by S. aureus according to the preliminary findings.•Recombinant endolysin Trx-SA1 might be an alternative treatment strategy for infections caused by S. aureus.
Methicillin-resistant Staphylococcus aureus (MRSA) has become a great threat to human and animal health and there is an urgent need to develop novel antibacterial agents to control this pathogen. The objective of this study was to obtain an active recombinant endolysin from the novel bacteriophage (IME-SA1), and conduct an efficacy trial of its effectiveness against bovine mastitis. We isolated a phage that was virulent and specific for S. aureus with an optimal multiplicity of infection of 0.01. Electron microscopy revealed that IME-SA1 was a member of the family Myoviridae, with an isometric head (98 nm) and a long contractile tail (200 nm). Experimental lysis experiments indicated the phage had an incubation period of 20 min with a burst size of 80. When host bacteria were in early exponential growth stages, a multiplicity of infection of 0.01 resulted in a complete bacterial lysis after 9 h. The endolysin gene (804 bp) was cloned into the pET-32a bacterial expression vector and recombinant endolysin Trx-SA1 was successfully obtained with molecular size of about 47 kDa. Preliminary results of therapeutic trials in cow udders showed that Trx-SA1 could effectively control mild clinical mastitis caused by S. aureus. The endolysin Trx-SA1 might be an alternative treatment strategy for infections caused by S. aureus, including MRSA.
